Gap19 TFA (1507930-57-5 free base)
CAS No. ——
Gap19 TFA (1507930-57-5 free base) ( —— )
产品货号. M30210 CAS No. ——
Gap19 TFA is a peptide derived from nine amino acids of Cx43 cytoplasmic ring (CL), an effective, selective connexin 43 (Cx43) half-channel blocker.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Gap19 TFA (1507930-57-5 free base)
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Gap19 TFA is a peptide derived from nine amino acids of Cx43 cytoplasmic ring (CL), an effective, selective connexin 43 (Cx43) half-channel blocker.
-
产品描述Gap19 TFA is a peptide derived from nine amino acids of Cx43 cytoplasmic ring (CL), an effective, selective connexin 43 (Cx43) half-channel blocker.(In Vitro):Gap19 TFA (250 μM; for 30 min ) decreases mitochondrial potassium uptake. Gap19 TFA (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells. Gap19 TFA (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes. Gap19 TFA (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo. (In Vivo):Gap19 TFA (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Cx43 Hemichannel
-
研究领域——
-
适应症——
化学信息
-
CAS Number——
-
分子量1275.5
-
分子式C57H97F3N14O15
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称Sequence:{Lys}{Gln}{Ile}{Glu}{Ile}{Lys}{Lys}{Phe}{Lys}
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
Boengler K, et al. Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol. 2013 Jun 6;4:73.
产品手册
关联产品
-
Humantenine
Humantenine is a indole alkaloid compound isolated from Gelsemium elegans.
-
AR-M 1000390 hydroch...
AR-M 1000390 (hydrochloride), also known as ARM-390, is a low-internalizing nonpeptidic δ-selective opioid receptor agonist; derivative of SNC 80.
-
Monomethyl lithosper...
Monomethyl lithospermate has potential antiviral activity, alleviating ischemic stroke injury in vivo in middle cerebral artery occlusion mice by activating PI5K/Akt signaling and protecting oxygen-glucose deprivation/reoxygenation-induced SHSY-3Y cells in vitro.